Background Lenvatinib is a multikinase inhibitor used in the treatment of locally advanced or metastatic differentiated thyroid carcinoma when progression is evident and other treatment alternatives are not viable ( Schlumberger et al. 2015
Macarena Contreras Angulo, Belén García Izquierdo, Laura Armengod Grao, and Nuria Palacios García
Vineeth Sukrithan, Prachi Jain, Manisha H Shah, and Bhavana Konda
patients. Unlike agents that target the MAPK pathway, various other therapies including retinoids and multitargeted KIs such as sorafenib and lenvatinib have failed to show clinically meaningful response in re-sensitizing RAI-R thyroid cancers to iodine
